Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) issued its earnings results on Thursday. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04, Zacks reports. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%.

Swedish Orphan Biovitrum Price Performance

Shares of Swedish Orphan Biovitrum stock opened at $49.03 on Thursday. The business has a 50-day moving average of $47.89 and a 200-day moving average of $42.01. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47. The company has a market capitalization of $17.45 billion, a PE ratio of 163.43 and a beta of 0.35. Swedish Orphan Biovitrum has a 1-year low of $28.93 and a 1-year high of $49.03.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BIOVF. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Zacks Research raised Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They set a “buy” rating on the stock. Finally, Pareto Securities cut Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.